<?xml version="1.0" encoding="UTF-8"?>
<ack>
 <title>Acknowledgements</title>
 <p>The trial is funded by Cancer Research UK ((A19272) CRUK/15/008) through the NCRI and Takeda Pharmaceutical Company. The trial is sponsored by the University of Leeds (Research &amp; Innovation Centre/Faculty of Medicine &amp; Health, Leeds Teaching Hospitals NHS Trust/University of Leeds, St James University Hospital, Leeds, LS9 7TF and is registered (ISRCTN10038996, EudraCT Number 2016-000905-35). The trial is running in collaboration with Haematology Malignancy Diagnostic ServiceÂ (HMDS), Leeds, Birmingham Myeloma Laboratory with the coordinating centre based at University of Leeds CTRU.</p>
 <sec id="FPar1">
  <title>Funding</title>
  <p id="Par133">The trial is funded by Cancer Research UK ((A19272) CRUK/15/008) through the NCRI with further unrestricted funding from Takeda Pharmaceutical Company. The funders had no role in the design, collection, analysis or collection of data; in writing the manuscript; or in the decision to submit the manuscript for publication.</p>
 </sec>
 <sec id="FPar2">
  <title>Availability of data and materials</title>
  <p id="Par134">Data sharing is not applicable to this article, as no datasets were generated or analysed during the current study. Patient Information Sheets, along with the study protocol, are available from the Trial Team upon reasonable request and with permission of the TMG.</p>
 </sec>
</ack>
